Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1958 1
1959 1
1960 1
1961 1
1962 1
1965 1
1966 1
1968 1
1972 2
1973 2
1974 1
1975 5
1976 7
1977 3
1978 4
1979 3
1980 7
1981 5
1982 4
1983 8
1984 4
1985 5
1986 5
1987 9
1988 6
1989 7
1990 6
1991 9
1992 6
1993 7
1994 5
1995 7
1996 5
1997 2
1998 9
1999 7
2000 13
2001 15
2002 2
2003 9
2004 11
2005 10
2006 22
2007 21
2008 22
2009 16
2010 26
2011 30
2012 29
2013 30
2014 35
2015 32
2016 43
2017 40
2018 37
2019 41
2020 48
2021 47
2022 46
2023 33

Text availability

Article attribute

Article type

Publication date

Search Results

740 results

Results by year

Filters applied: . Clear all
Page 1
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: helland a. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. Lancet Oncol. 2017. PMID: 28919011 Clinical Trial.
Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A. Stankovic B, et al. Among authors: helland a. Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018. Front Immunol. 2019. PMID: 30774636 Free PMC article.
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.
Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ, Branca RM, Planck M, Staaf J, Orre LM. Lehtiö J, et al. Among authors: helland a. Nat Cancer. 2021 Nov;2(11):1224-1242. doi: 10.1038/s43018-021-00259-9. Epub 2021 Nov 22. Nat Cancer. 2021. PMID: 34870237 Free PMC article.
Nye anbefalinger ved serumkonsentrasjonsmålinger av sentralstimulerende legemidler.
Frost J, Bernard JP, Dietrichs ES, Kjeldstadli K, Riedel B, Skråstad RB, Vevelstad M, Helland A. Frost J, et al. Among authors: helland a. Tidsskr Nor Laegeforen. 2019 Sep 23;139(13). doi: 10.4045/tidsskr.19.0385. Print 2019 Sep 24. Tidsskr Nor Laegeforen. 2019. PMID: 31556515 Free article. Norwegian. No abstract available.
European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe.
Nacul L, Authier FJ, Scheibenbogen C, Lorusso L, Helland IB, Martin JA, Sirbu CA, Mengshoel AM, Polo O, Behrends U, Nielsen H, Grabowski P, Sekulic S, Sepulveda N, Estévez-López F, Zalewski P, Pheby DFH, Castro-Marrero J, Sakkas GK, Capelli E, Brundsdlund I, Cullinan J, Krumina A, Bergquist J, Murovska M, Vermuelen RCW, Lacerda EM. Nacul L, et al. Among authors: helland ib. Medicina (Kaunas). 2021 May 19;57(5):510. doi: 10.3390/medicina57050510. Medicina (Kaunas). 2021. PMID: 34069603 Free PMC article.
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Novello S, et al. Among authors: helland a. Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121. Ann Oncol. 2018. PMID: 29668860 Free PMC article. Clinical Trial.
Authors' response.
Thorud HM, Helland M, Aarås A, Kvikstad TM, Lindberg LG, Horgen G. Thorud HM, et al. Among authors: helland m. Optom Vis Sci. 2015 Jan;92(1):e27. doi: 10.1097/OPX.0000000000000457. Optom Vis Sci. 2015. PMID: 25437909 No abstract available.
[Groundbreaking basic research].
Helland Å. Helland Å. Tidsskr Nor Laegeforen. 2018 Dec 10;138(20). doi: 10.4045/tidsskr.18.0802. Print 2018 Dec 11. Tidsskr Nor Laegeforen. 2018. PMID: 30539600 Free article. Norwegian. No abstract available.
Validity and Reliability of a Motorized Sprint Resistance Device.
Rakovic E, Paulsen G, Helland C, Haugen T, Eriksrud O. Rakovic E, et al. Among authors: helland c. J Strength Cond Res. 2022 Aug 1;36(8):2335-2338. doi: 10.1519/JSC.0000000000003830. Epub 2022 Jan 5. J Strength Cond Res. 2022. PMID: 35916750
740 results